Alere (ALR) Receives Price Target

Alere (ALR) : The consensus price target for Alere (ALR) is $54 for the short term with a standard deviation of $4. The most optimist securities analyst among the 4 who monitor the stock believes that the stock can reach $56, however, the pessimist price target for the company is $48.

Alere (ALR) : The consensus on Alere (ALR) based on 5 analyst recommendation on the company stock is 1.8, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 3 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 2 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.


Also, BTIG Research upgrades its view on Alere (NYSE:ALR) according to the research report released by the firm to its investors. The shares have now been rated Buy by the stock experts at the ratings house. Earlier, the shares had a rating of Neutral. BTIG Research announces the current price target of $48 per share on Alere . The rating by the firm was issued on August 8, 2016.

Alere (NYSE:ALR): The stock opened at $38.70 on Thursday but the bulls could not build on the opening and the stock topped out at $39.12 for the day. The stock traded down to $38.31 during the day, due to lack of any buying support eventually closed down at $38.44 with a loss of -1.76% for the day. The stock had closed at $39.13 on the previous day. The total traded volume was 776,270 shares.

Alere Inc. is a provider of health information through diagnostic tests. The Company operates through professional diagnostics, patient self-testing, consumer diagnostics and, corporate and other segments. The professional diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests marketed to medical professionals and laboratories for detection of diseases and conditions within its areas of focus. The patient-self testing segment provides services designed to provide physicians with actionable data that allow them to make decisions in real time, deliver care, and put the individuals they treat on a pathway to better health. The consumer diagnostics segment consists primarily of manufacturing operations related to its role as the exclusive manufacturer of products for SPD Swiss Precision Diagnostics (SPD), its 50/50 joint venture with The Procter & Gamble Company (P&G).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.